Short term effects of nasal high flow therapy on autonomic nervous system function and respiration in patients with neuromuscular diseases

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013903

Enrollment

Registered

2018-04-04

Start date

2018-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G12 E74

Interventions

Group 1: In the afternoon 12 patients with an ongoing nocturnal NIV (Non-invasive ventilation) therapy for hypoventilation due to a NMD (Numerous neuromuscular disorders) will be attached to a full c

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: a. Age > 18 years (no age limit) b. able to consent c. proven NMD d. ongoing nocturnal NIV therapy with a nasal mask for hypoventilation due to a NMD e. good tolerance of and adherence to the ongoing NIV therapy with minimal nasal mask-related problems/discomfort f. no vital indication for NIV use at night

Exclusion criteria

Exclusion criteria: - other severe internistic pre-existing conditions, especially insulin-dependent diabetes or severe renal impairment - severe neurological pre-existing conditions such as stroke, especially brainstem infarction - intake of opioids - severe psychiatric pre-existing conditions

Design outcomes

Primary

Measure	Time frame
Muscular sympathetic nerve activity [Burst rate/min; Burst rate/100 beats], high frequency component of heart rate variability [%], low frequency component of diastolic blood pressure variability [%] -> measured at daytime and under the above mentioned interventions	—

Secondary

Measure	Time frame
Heart rate [bpm], systolic blood pressure [mmHG], diastolic blood pressure [mmHG], stroke volume index [L/min/m²], high frequency component of diastolic blood pressure variability[%], low frequency component of heart rate variability [%], respiratory rate [/min], tidal volume [ml], minute ventilation [L/min], oxygen saturation [%], transcutaneous CO2 [mmHG], Borg Dyspnoea Scale [points] -> measured at daytime and under the above mentioned interventions	—

Measure

Time frame

Heart rate [bpm], systolic blood pressure [mmHG], diastolic blood pressure [mmHG], stroke volume index [L/min/m²], high frequency component of diastolic blood pressure variability[%], low frequency component of heart rate variability [%], respiratory rate [/min], tidal volume [ml], minute ventilation [L/min], oxygen saturation [%], transcutaneous CO2 [mmHG], Borg Dyspnoea Scale [points] -> measured at daytime and under the above mentioned interventions

—

Countries

Germany

Contacts

Public ContactMatthias Boentert

Department für Neurologie- Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster

matthias.boentert@ukmuenster.de00492518344458

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026